RA and retinol deficiency have been shown to have a striking impact in the structure and function of the cornea, and are responsible for the onset and progression of diseases affecting this organ, such as xerophtalmia
4 and keratoconus.
15 Surprisingly, although stromal disorganization and thinning are common hallmarks of these pathologies,
5,16 few studies focus on the role of RA or retinol on keratocyte biology. Several mechanisms have been proposed for the pathophysiology of these diseases, namely based on changes in the expression of MMPs and corresponding tissue inhibitors of metalloproteases (TIMPs)
17 or increase of oxidative stress.
16 Here, we propose a mechanism where endogenous RA directly regulates the various biochemical and molecular pathways involved in these diseases (
Fig. 8). The effects of RA in the expression of MMPs and scleral ECM components shown in this and in previous studies
11,18 support its role in maintaining the proper phenotype of keratocytes. On the other hand, RA was shown to prevent the generation of free-radical–induced oxidative injury and apoptosis in corneal endothelial cells.
19 Furthermore, RA has been successfully tested as an antioxidant in scavenging assays against nitric oxide, lipid peroxide, and hydroxyl and superoxide radicals in mice.
20 As such, and according to our proposed mechanism, the absence of RA would compromise keratocyte homeostasis, free-radical scavenger generation, and ECM turnover and maintenance. Ultimately, a chronic deprivation of RA in the cornea would result in increased MMP activity, which would then affect the integrity of stromal lamellae and result in corneal degeneration and disease (
Fig. 8). Interestingly, a very similar mechanism has been described for the effect of retinoids in human skin in vivo, where RA inhibits UV light-induced, MAP kinase-mediated MMP activation, and consequently, skin degradation.
21 Furthermore, our model would explain why topical application of retinoids lack efficacy in treating ocular surface diseases,
22 as lipophilic RA molecules applied topically to the cornea would be unable to reach keratocytes and the interior of the stroma. This, together with the inhibitory effects of RA on androgens,
23 may contribute to the high variability of patient response to these treatments.
24